Article

Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients with Chronic Hepatitis C Virus Infection

2020-10-05

Abstract excerpt

<h4>Aims: </h4> Yimitasvir is a novel, oral hepatitis C virus (HCV) non-structural protein 5A inhibitor for the treatment of chronic HCV genotype 1 infection. The objective of this analysis was to develop a population pharmacokinetic model of yimitasvir in Chinese healthy volunteers and HCV infection patients. Methods The model was performed using data from 219 subjects across 6 studies. Nonlinear mixed effects mo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 718805ba-6fc6-5139-9f8d-54b136df0b61
DOI: 10.22541/au.160193339.96141209/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients with Chronic Hepatitis C Virus InfectionDOI 10.22541/au.160193339.96141209/v1Read

[A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C].Semantic proximity Read

A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.Semantic proximity Read

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.Semantic proximity Read

Population Pharmacokinetics Study of Morinidazole in Patients with Moderate Hepatic ImpairmentSemantic proximity Read

Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.Semantic proximity Read

Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.Semantic proximity Read

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.Semantic proximity Read

Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection.Semantic proximity Read

Safety and pharmacokinetic profile of pretomanid (PA-824) in healthy Chinese participants: Results of a phase I single dose escalation studySemantic proximity Read

Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.Semantic proximity Read

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.Semantic proximity Read

Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjectsSemantic proximity Read